DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks(Isala), Jan H.M. Schellens(Utrecht University), Annemieke Cats(Oncode Institute), Albert J. ten Tije(Amphia Ziekenhuis), Femke M. de Man(Erasmus MC), Hans Gelderblom(Leiden University Medical Center), Frank J. Jeurissen(Medisch Centrum Haaglanden), Didier Meulendijks(AstraZeneca (Brazil)), Henk‐Jan Guchelaar(Leiden University Medical Center), Emma Kienhuis(Erasmus MC), Vincent O. Dezentjé(The Netherlands Cancer Institute), Hilde Rosing(The Netherlands Cancer Institute), Paul Hamberg(Sint Franciscus Gasthuis), Peter Nieboer, Erik van Werkhoven(The Netherlands Cancer Institute), Carin A.T.C. Lunenburg(Leiden University Medical Center), Miriam Koopman(Utrecht University), Jos H. Beijnen(The Netherlands Cancer Institute), Jesse J. Swen(Leiden University Medical Center), Helga Droogendijk(Bravis Ziekenhuis), Alexander L.T. Imholz(Deventer Ziekenhuis), André B. P. Kuilenburg(Amsterdam University Medical Centers), Ron H.J. Mathijssen(Erasmus MC), Arnold Baars(Ziekenhuis Gelderse Vallei), Rob L. H. Jansen(Maastricht University), Geert Frederix(University Medical Center Utrecht), Ron H. N. van Schaik(Erasmus MC), Geert-Jan Creemers(Radboud University Nijmegen), Caroline M.P.W. Mandigers(Canisius-Wilhelmina Ziekenhuis), Marlène H. W. van de Poel(Laurentius Ziekenhuis)
Cited by 419
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k